CD38 Targeting Opens a New Front Against Treatment-Resistant Immune Thrombocytopenia
Long-lived plasma cells hiding in bone marrow sustain autoimmune platelet destruction. CD38-directed antibodies may finally clear them.
Summary
Immune thrombocytopenia (ITP) is an autoimmune condition where the body destroys its own platelets, causing dangerous bleeding. Standard therapies often fail to produce lasting remission because long-lived plasma cells in the bone marrow keep churning out antiplatelet antibodies. This review examines CD38, a protein abundantly expressed on these plasma cells, as a precision therapeutic target. CD38-directed monoclonal antibodies — already proven in multiple myeloma — can deplete the autoantibody-producing cells, reduce platelet phagocytosis, and modulate immune effector activity. The authors synthesize the biological rationale, emerging clinical evidence, and future directions including biomarker-guided combination strategies that could reshape how refractory ITP is treated.
Detailed Summary
Immune thrombocytopenia affects patients across all age groups and carries significant bleeding risk. Although corticosteroids, intravenous immunoglobulin, and thrombopoietin receptor agonists are mainstays of treatment, many patients relapse or develop refractory disease. Understanding why remission is so difficult to sustain is critical to improving outcomes.
A key culprit identified in this review is the migration of antigen-specific plasmablasts from the spleen into the bone marrow, where they mature into long-lived plasma cells. These cells persist in protective niches and continuously produce antiplatelet autoantibodies, effectively resetting the disease even after surface-level immune suppression.
CD38 is a multifunctional enzyme and receptor expressed on plasma cells, B cells, NK cells, macrophages, and activated T cells. It participates in NAD⁺ metabolism and calcium signaling, making it a central node in immune cell communication. Its high expression on the very cells driving chronic ITP makes it an attractive target.
CD38-directed monoclonal antibodies such as daratumumab work through multiple mechanisms simultaneously: depleting plasmablasts and long-lived plasma cells, attenuating Fcγ receptor-mediated platelet phagocytosis by macrophages, and modulating cytotoxic lymphocyte function. Together, these effects could address the root cause of treatment resistance rather than just downstream inflammation.
The review calls for biomarker-guided patient selection and combination regimens to maximize durable responses. Caveats include the fact that most supporting data comes from case reports and small series rather than randomized trials, and CD38 is also expressed on beneficial regulatory immune populations, raising questions about off-target immunosuppression.
Key Findings
- Long-lived bone marrow plasma cells sustain antiplatelet autoantibody production, explaining why ITP relapses after standard therapy.
- CD38 is highly expressed on plasma cells, plasmablasts, NK cells, and macrophages central to ITP pathogenesis.
- CD38-targeted antibodies deplete autoantibody-producing cells and attenuate Fcγ receptor-mediated platelet clearance simultaneously.
- Biomarker-guided, combination-based CD38 strategies are proposed as the next step in refractory ITP treatment algorithms.
- NAD⁺/Ca²⁺ signaling through CD38 integrates immune crosstalk in bone marrow niches that protect pathogenic plasma cells.
Methodology
This is a narrative review synthesizing existing literature on CD38 biology, ITP pathogenesis, and emerging clinical evidence for CD38-targeted therapies. No original experimental or trial data were generated. The authors draw on mechanistic studies, case reports, and early clinical series to construct their therapeutic framework.
Study Limitations
The review is based on an abstract only, limiting assessment of evidence quality and the breadth of clinical data cited. Most clinical experience with CD38 inhibition in ITP appears to derive from small case series rather than randomized controlled trials. CD38 is also expressed on regulatory immune cells, and broad depletion could carry unintended immunosuppressive consequences.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: